Merseyside Inter Agency Drug Misuse Database

January – March 2009

Warrington DAAT

Quarter 4 2008/09

**Lloyd Baron, Steven Griffith,
Martin Chandler, Jim McVeigh**

DRAFT REPORT
The final version will be available on the IAD website

www.cph.org.uk/iad

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531
m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 4521
L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

National Drug Treatment Monitoring System (NDTMS) 16

Combined Datasets 19

Cross Matched Datasets 20

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)
Quarter 4 (2008/09)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	27	81.8
Female	6	18.2
Age Group		
Under 18	0	0.0
18-19	1	3.0
20-24	4	12.1
25-29	9	27.3
30-34	5	15.2
35-39	6	18.2
40-44	5	15.2
45+	3	9.1
Total	33	100

Table 2: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	2	2.7	2	8.7	4	4.1
20-24	20	26.7	2	8.7	22	22.4
25-29	16	21.3	3	13.0	19	19.4
30-34	11	14.7	8	34.8	19	19.4
35-39	14	18.7	5	21.7	19	19.4
40-44	8	10.7	2	8.7	10	10.2
45+	4	5.3	1	4.3	5	5.1
Total	75	100	23	100	98	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	1	0
Benzodiazepines	5	3
Cannabis	2	2
Crack	10	7
Cocaine	3	3
Ecstasy	0	0
Heroin	20	0
Methadone	3	0
Subutex	0	0
Other	0	0

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

PROBATION
Quarter 4 (2008/09)

Introduction

Data is provided by Cheshire Probation Services. Data relates to individuals reported through OASys with a reported substance use problem. Individuals who are on ASROs or similar treatment orders are reported to NDTMS.

NOTE: Probation figures are based on DAT of Residence, NOT DAT of contact as with other datasets.

Table 4: Probation Clients by Gender and Age Group

Gender	n	%
Male	79	90.8
Female	8	9.2
Age Group		
Under 18	0	0.0
18-19	8	9.2
20-24	15	17.2
25-29	13	14.9
30-34	17	19.5
35-39	10	11.5
40-44	9	10.3
45+	15	17.2
Total	*87*	*100*

Table 5: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	n	%	n	%	*n*	*%*
Under 18	1	<1	0	0.0	*1*	*<1*
18-19	25	9.0	2	5.7	*27*	*8.6*
20-24	50	18.0	8	22.9	*58*	*18.5*
25-29	54	19.4	8	22.9	*62*	*19.8*
30-34	39	14.0	8	22.9	*47*	*15.0*
35-39	42	15.1	5	14.3	*47*	*15.0*
40-44	30	10.8	1	2.9	*31*	*9.9*
45+	37	13.3	3	8.6	*40*	*12.8*
Total	*278*	*100*	*35*	*100*	*313*	*100*

Table 6: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	1	1
Benzodiazepines	2	0
Cannabis	1	5
Crack	3	4
Cocaine	0	0
Ecstasy	0	0
Heroin	1	5
Methadone	0	0
Prescription Drugs	0	1
Other	0	0

Table 6 shows the number of people reporting daily or weekly use of specific drugs. This is to reflect reporting of polydrug use through Probation data. No totals are given as clients can report daily or weekly use of more than one drug and may therefore be double counted between drugs.

ASROs
- 2 ASROs were commenced during Q4
- 2 individuals commenced ASROs during Q4
- 14 ASROs were terminated during Q4
- 8 individuals had their ASROs terminated during Q4

SYRINGE EXCHANGE SERVICES

Quarter 4 (2008/09)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 7: Individuals by Gender

New Clients	n	%
Male	12	92.3
Female	1	7.7
Total	13	100
All Clients		
Male	81	90.0
Female	9	10.0
Total	90	100

Table 8: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	3	75.0
Female	1	25.0
Total	4	100
All Clients		
Male	25	73.5
Female	9	26.5
Total	34	100

Table 9: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	7.7	1	1.1
20-24	6	46.2	20	22.2
25-29	3	23.1	23	25.6
30-34	2	15.4	15	16.7
35-39	0	0.0	16	17.8
40-44	1	7.7	10	11.1
45+	0	0.0	5	5.6
Total	13	100	90	100

Table 10: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	1	25.0	8	23.5
25-29	1	25.0	6	17.6
30-34	2	50.0	6	17.6
35-39	0	0.0	8	23.5
40-44	0	0.0	5	14.7
45+	0	0.0	1	2.9
Total	4	100	34	100

Table 11: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	1.2	0	0.0
20-24	17	21.0	3	33.3
25-29	21	25.9	2	22.2
30-34	13	16.0	2	22.2
35-39	16	19.8	0	0.0
40-44	9	11.1	1	11.1
45+	4	4.9	1	11.1
Total	81	100	9	100

Table 12: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	5	20.0	3	33.3
25-29	4	16.0	2	22.2
30-34	4	16.0	2	22.2
35-39	8	32.0	0	0.0
40-44	4	16.0	1	11.1
45+	0	0.0	1	11.1
Total	25	100	9	100

Table 13: Year to Date, by Gender & Age Group

Age Group	Gender					
	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	5	2.4	0	0.0	5	2.2
20-24	43	20.3	5	29.4	48	21.0
25-29	50	23.6	4	23.5	54	23.6
30-34	39	18.4	2	11.8	41	17.9
35-39	43	20.3	2	11.8	45	19.7
40-44	22	10.4	3	17.6	25	10.9
45+	10	4.7	1	5.9	11	4.8
Total	212	100	17	100	229	100

Table 14: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender					
	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	0	0.0	0	0.0	0	0.0
20-24	6	9.0	5	29.4	11	13.1
25-29	10	14.9	4	23.5	14	16.7
30-34	13	19.4	2	11.8	15	17.9
35-39	25	37.3	2	11.8	27	32.1
40-44	13	19.4	3	17.6	16	19.0
45+	0	0.0	1	5.9	1	1.2
Total	67	100	17	100	84	100

Table 15: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	2	16.7	1	100
Methadone	0	0.0	0	0.0
Melanotan	0	0.0	0	0.0
Steroids	9	75.0	0	0.0
Other	1	8.3	0	0.0
Total	12	100	1	100

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 16: Main Drug of Use for All Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	23	28.4	8	88.9
Methadone	0	0.0	1	11.1
Melanotan	0	0.0	0	0.0
Steroids	56	69.1	0	0.0
Other	2	2.5	0	0.0
*Total**	51	100	9	100

*Please Note: Totals may not be concurrent due to the reporting of Melanotan clients. Further details are available on request.

Table 17: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Ampheta-mine		Benzodi-azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
18-19	-	-	-	-	-	-	-	-	0	0.0	-	-	1	11.1
20-24	-	-	-	-	-	-	-	-	1	33.3	-	-	5	55.6
25-29	-	-	-	-	-	-	-	-	1	33.3	-	-	2	22.2
30-34	-	-	-	-	-	-	-	-	1	33.3	-	-	0	0.0
35-39	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
40-44	-	-	-	-	-	-	-	-	0	0.0	-	-	1	11.1
45+	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
*Total**	-	-	-	-	-	-	-	-	3	100	-	-	9	100

* % Totals are by Drug, not Age Group.

Please Note: Due to a change in reporting methods main drug of use by age group will only be reported for new clients. Information on age group for all clients is available on request.

PHARMACY SYRINGE EXCHANGE

Table 18: Individuals by Gender

New Clients	n	%
Male	29	87.9
Female	4	12.1
Total	33	100
All Clients		
Male	96	86.5
Female	15	13.5
Total	111	100

Table 19: Individuals by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	5	15.2	7	6.3
18-19	5	15.2	11	9.9
20-24	7	21.2	21	18.9
25-29	4	12.1	16	14.4
30-34	6	18.2	18	16.2
35-39	3	9.1	18	16.2
40-44	1	3.0	9	8.1
45+	2	6.1	11	9.9
Total	33	100	111	100

Table 20: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		**Female**			
Age Group	**n**	**%**	**n**	**%**	**n**	**%**
Under 18	19	4.6	1	1.8	20	4.3
18-19	44	10.8	4	7.1	48	10.3
20-24	112	27.4	5	8.9	117	25.2
25-29	65	15.9	18	32.1	83	17.8
30-34	72	17.6	9	16.1	81	17.4
35-39	58	14.2	11	19.6	69	14.8
40-44	21	5.1	3	5.4	24	5.2
45+	18	4.4	5	8.9	23	4.9
Total	409	100	56	100	465	100

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 21: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	41	91.1
Female	4	8.9
Total	45	100
All Clients		
Male	171	88.1
Female	23	11.9
Total	194	100

Table 22: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	32	88.9
Female	4	11.1
Total	36	100
All Clients		
Male	115	83.3
Female	23	16.7
Total	138	100

*Only known steroid users, based on Agency SES data, have been omitted.

Table 23: Individuals in Syringe Exchange, by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	5	11.1	7	3.6
18-19	6	13.3	12	6.2
20-24	13	28.9	41	21.1
25-29	7	15.6	36	18.6
30-34	7	15.6	32	16.5
35-39	3	6.7	32	16.5
40-44	2	4.4	18	9.3
45+	2	4.4	16	8.2
Total	45	100	194	100

Table 24: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	5	13.9	7	5.1
18-19	5	13.9	11	8.0
20-24	8	22.2	29	21.0
25-29	5	13.9	19	13.8
30-34	7	19.4	23	16.7
35-39	3	8.3	24	17.4
40-44	1	2.8	13	9.4
45+	2	5.6	12	8.7
Total	36	100	138	100

Table 25: Year to Date, by Gender & Age Group

Age Group	Gender				*Total in Age Group*	
	Male		Female			
	n	%	n	%	*n*	*%*
Under 18	18	3.1	1	1.5	19	2.9
18-19	49	8.4	4	5.9	53	8.2
20-24	148	25.5	9	13.2	157	24.2
25-29	109	18.8	22	32.4	131	20.2
30-34	102	17.6	9	13.2	111	17.1
35-39	89	15.3	11	16.2	100	15.4
40-44	38	6.6	7	10.3	45	6.9
45+	27	4.7	5	7.4	32	4.9
Total	580	100	68	100	648	100

Table 26: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	6,362	2,975	9,337	44,254

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)
Quarter 4 (2008/09)

Background
The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients
Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 27: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	94	81.7
Female	21	18.3
Total	115	100
All Clients		
Male	224	26.2
Female	631	73.8
Total	855	100

Table 28: Year to Date, by Gender

New Clients	n	%
Male	266	76.0
Female	84	24.0
Total	350	100
All Clients		
Male	666	74.1
Female	233	25.9
Total	899	100

Table 29: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	8	7.0	98	11.5
18-19	4	3.5	29	3.4
20-24	20	17.4	85	9.9
25-29	26	22.6	157	18.4
30-34	22	19.1	189	22.1
35-39	17	14.8	175	20.5
40-44	10	8.7	74	8.7
45+	8	7.0	48	5.6
Total	115	100	855	100

Table 30: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	37	10.6	98	10.9
18-19	11	3.1	29	3.2
20-24	41	11.7	93	10.3
25-29	72	20.6	166	18.5
30-34	64	18.3	199	22.1
35-39	71	20.3	182	20.2
40-44	33	9.4	82	9.1
45+	21	6.0	50	5.6
Total	350	100	899	100

Table 31: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	113	98.3	831	97.2
White Irish	0	0.0	6	<1
Other White	0	0.0	1	<1
White & Black Caribbean	1	<1	3	<1
Other Black	0	0.0	1	<1
White & Asian	0	0.0	0	0.0
Other Asian	0	0.0	1	<1
Caribbean	0	0.0	0	0.0
Chinese	0	0.0	0	0.0
Other	1	<1	7	<1
Unknown	0	0.0	5	<1
Total	115	100	855	100

Table 32: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	60	52.2	514	60.1
Methadone	1	<1	35	4.1
Other Opiates	2	1.7	15	1.8
Benzodiazepine	0	0.0	8	<1
Amphetamines	2	1.7	17	2.0
Cocaine	26	22.6	111	13.0
Crack	5	4.3	21	2.5
Ecstasy	1	<1	5	<1
Prescription Drugs	0	0.0	4	<1
Cannabis	17	14.8	118	13.8
Other/Unknown	1	<1	7	<1
Total	*115*	*100*	*855*	*100*

COMBINED DATASETS
Quarter 4 (2008/09)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 33: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	845	77.3
Female	248	22.7
Age Group		
Under 18	105	9.6
18-19	50	4.6
20-24	140	12.8
25-29	199	18.2
30-34	227	20.8
35-39	200	18.3
40-44	99	9.1
45+	73	6.7
Total	1,093	100

Table 34: Year to Date, by Gender and Age Group

	Gender					
	Male		**Female**		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	*n*	**%**
Under 18	86	6.3	33	10.5	119	7.0
18-19	82	6.0	18	5.7	100	5.9
20-24	261	19.0	34	10.8	295	17.5
25-29	252	18.4	67	21.3	319	18.9
30-34	252	18.4	76	24.1	328	19.4
35-39	228	16.6	50	15.9	278	16.5
40-44	121	8.8	22	7.0	143	8.5
45+	91	6.6	15	4.8	106	6.3
Total	1,373	100	315	100	1,688	100

CROSS-MATCHED DATASETS
Quarter 4 (2008/09)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

AGENCY (90) — 20 Male 6 Female — NDTMS (855)

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

PHARMACY (111) — 31 Male 7 Female — NDTMS (855)